Suppliers and packagers for jakafi

jakafi

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192	NDA	Incyte Corporation	50881-005-60	60 TABLET in 1 BOTTLE, PLASTIC (50881-005-60)	2011-11-16
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192	NDA	Incyte Corporation	50881-010-01	28 TABLET in 1 BOTTLE, PLASTIC (50881-010-01)	2011-11-16
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192	NDA	Incyte Corporation	50881-010-60	60 TABLET in 1 BOTTLE, PLASTIC (50881-010-60)	2011-11-16
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192	NDA	Incyte Corporation	50881-015-60	60 TABLET in 1 BOTTLE, PLASTIC (50881-015-60)	2011-11-16
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192	NDA	Incyte Corporation	50881-020-60	60 TABLET in 1 BOTTLE, PLASTIC (50881-020-60)	2011-11-16
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192	NDA	Incyte Corporation	50881-025-60	60 TABLET in 1 BOTTLE, PLASTIC (50881-025-60)	2011-11-16

Jakafi (Ruxolitinib) Supply Chain Analysis

Last updated: February 19, 2026

Jakafi, developed by Incyte and marketed by Novartis, is a Janus kinase (JAK) inhibitor used to treat myelofibrosis and polycythemia vera. The drug's complex manufacturing process relies on a global network of specialized suppliers for active pharmaceutical ingredients (APIs), key intermediates, and excipients. Understanding these suppliers is critical for ensuring consistent production, mitigating supply chain risks, and assessing competitive landscape.

What are the Key Components of Jakafi?

Jakafi's active pharmaceutical ingredient (API) is ruxolitinib. The synthesis of ruxolitinib involves several complex chemical steps, requiring specific raw materials and intermediates. The final drug product also incorporates various excipients that ensure stability, bioavailability, and effective delivery.

Active Pharmaceutical Ingredient (API) - Ruxolitinib

Ruxolitinib's chemical structure is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile. The synthesis of this molecule requires specialized chemical expertise and advanced manufacturing capabilities.

Key Intermediates

The production of ruxolitinib necessitates a series of intermediate compounds. Identifying the suppliers of these specific intermediates provides insight into the depth of the supply chain. Examples of precursor chemicals or key building blocks in the synthesis might include substituted pyrimidines and pyrroles, as well as cyclopentyl derivatives.

Excipients

The formulation of Jakafi tablets involves several inactive ingredients, or excipients, which are critical for the drug's physical properties and performance. These can include:

• Fillers/Diluents: Such as microcrystalline cellulose, which provides bulk to the tablet.
• Binders: Like hydroxypropyl cellulose, which holds the tablet ingredients together.
• Disintegrants: Such as croscarmellose sodium, which helps the tablet break down in the body.
• Lubricants: For instance, magnesium stearate, which prevents sticking during tablet manufacturing.
• Coating Agents: For tablet film coating, contributing to stability and ease of swallowing.

Who are the Primary Suppliers for Jakafi's Components?

The supply chain for Jakafi is multi-layered, involving suppliers of the API itself, critical intermediates, and the excipients used in the final drug product. Companies in this ecosystem range from large chemical manufacturers to specialized contract development and manufacturing organizations (CDMOs).

API and Intermediate Suppliers

Direct API suppliers for ruxolitinib are typically CDMOs with advanced chemical synthesis capabilities and Good Manufacturing Practice (GMP) certifications. Incyte and Novartis may source ruxolitinib API from one or more qualified manufacturers globally. These suppliers are vetted for quality, regulatory compliance, and production capacity.

• Lonza: A significant player in API manufacturing, Lonza has broad capabilities in complex organic synthesis and microbial fermentation, often serving as a CDMO for innovative pharmaceuticals. Their facilities in Visp, Switzerland, and other global sites are equipped for large-scale API production.
• Catalent: Known for its integrated drug development and manufacturing services, Catalent offers API development and manufacturing for a range of complex molecules. Their expertise spans various therapeutic areas, including oncology.
• WuXi AppTec: A prominent China-based CDMO, WuXi AppTec provides a comprehensive suite of services, including API process development and manufacturing, for global pharmaceutical companies. They have a substantial footprint in small molecule synthesis.
• Bachem: Specializing in the manufacturing of complex chemical intermediates and APIs, Bachem has a strong reputation for peptide and oligonucleotide synthesis, but also for other complex small molecules.

It is important to note that specific supplier relationships for proprietary APIs are often confidential. However, the scale and complexity of ruxolitinib synthesis suggest reliance on CDMOs with established expertise in advanced organic chemistry and large-scale GMP production. The intermediates required for ruxolitinib synthesis are likely produced by specialized fine chemical manufacturers.

Excipient Suppliers

The excipients used in Jakafi are sourced from established global chemical suppliers that specialize in pharmaceutical-grade ingredients. These suppliers must adhere to strict quality standards and regulatory requirements set by health authorities.

• International Flavors & Fragrances (IFF) - formerly DuPont Nutrition & Biosciences: A major supplier of functional excipients, including microcrystalline cellulose (MCC) and other cellulosic derivatives. Their EMDEX™ MCC is a widely used binder and diluent in tablet formulations.
• Ashland: A leading supplier of high-performance excipients for oral solid dosage forms. Products include binders, disintegrants, and film coatings. Their VIVAPHARM® cellulose derivatives and KLUCEL™ hydroxypropyl cellulose are commonly employed in pharmaceutical formulations.
• JRS Pharma: A global manufacturer of functional excipients, including binders, disintegrants, and fillers. Their VIVAPUR® MCC and other specialized excipients are used across a broad range of oral solid dosage forms.
• BASF: A diversified chemical company that supplies a range of pharmaceutical excipients, including binders, disintegrants, and solubility enhancers. Their portfolio includes materials like Kollidon® povidones and Soluplus® povidones.
• Merck KGaA (MilliporeSigma in the U.S. and Canada): Supplies a broad range of chemicals and reagents, including high-purity excipients for pharmaceutical manufacturing.

What are the Regulatory and Quality Considerations for Suppliers?

Pharmaceutical supply chains are subject to stringent regulatory oversight to ensure patient safety and drug efficacy. Suppliers of APIs, intermediates, and excipients must comply with various international standards.

Good Manufacturing Practice (GMP)

All suppliers involved in the manufacturing of Jakafi components must adhere to current Good Manufacturing Practice (cGMP) regulations as defined by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global health authorities. This includes:

• Quality Management Systems: Robust systems for process control, documentation, and deviation management.
• Facility and Equipment: Maintenance of sterile or controlled environments, calibrated equipment, and validated processes.
• Personnel Training: Adequately trained staff in manufacturing, quality control, and assurance.
• Raw Material Control: Rigorous testing and qualification of incoming raw materials.
• Process Validation: Demonstrating that manufacturing processes consistently produce products meeting predetermined specifications.

Drug Master Files (DMFs)

API manufacturers typically file Drug Master Files (DMFs) with regulatory agencies. A DMF is a submission to regulatory authorities (like the FDA) containing confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs. This allows regulatory agencies to review proprietary information without disclosing it to the drug product applicant.

Supply Chain Audits and Qualification

Incyte and Novartis conduct thorough audits and qualification processes for all critical suppliers. These audits assess:

• Quality Systems: Compliance with cGMP and company-specific quality standards.
• Technical Capabilities: Ability to consistently produce materials meeting specifications.
• Capacity and Reliability: Assurance of sufficient production capacity and a track record of dependable supply.
• Regulatory Compliance History: A clear record of adherence to regulatory requirements.

Supply Chain Security and Traceability

Ensuring the integrity and security of the supply chain is paramount. This involves measures to prevent counterfeiting, diversion, and contamination. Traceability systems are implemented to track materials from their origin to the final drug product.

What are the Potential Supply Chain Risks for Jakafi?

The global nature of pharmaceutical manufacturing exposes Jakafi to various potential supply chain risks that could impact availability and cost.

Single Source Dependence

Reliance on a single supplier for a critical API intermediate or specialized excipient creates a significant vulnerability. Any disruption at that supplier's facility, whether due to manufacturing issues, regulatory actions, natural disasters, or geopolitical events, could lead to drug shortages.

Geopolitical Instability

Many API and intermediate manufacturers are located in Asia, particularly China and India. Geopolitical tensions, trade disputes, or political instability in these regions can disrupt production and logistics.

Regulatory Changes

Changes in regulatory requirements in manufacturing countries or importing countries can necessitate process modifications or increased compliance costs for suppliers, potentially leading to supply disruptions or price increases.

Raw Material Price Volatility

The cost of raw materials used in API synthesis can fluctuate due to market demand, commodity prices, and environmental regulations impacting their extraction or production.

Natural Disasters and Pandemics

Events such as earthquakes, floods, or global pandemics (e.g., COVID-19) can severely disrupt manufacturing operations and global transportation networks, impacting the availability of both APIs and excipients.

Intellectual Property Disputes

While Jakafi itself is patented, the manufacturing processes for its intermediates or the API itself may involve proprietary technologies. Disputes over intellectual property could affect the ability of certain suppliers to continue production.

Transportation and Logistics

The movement of sensitive pharmaceutical ingredients across borders involves complex logistics, customs clearance, and specialized transportation to maintain product integrity. Disruptions in shipping routes, port congestion, or increased freight costs can impact timelines and cost of goods.

What is the Competitive Landscape for Jakafi Suppliers?

The competitive landscape for Jakafi suppliers is characterized by the need for highly specialized capabilities, robust quality systems, and regulatory compliance.

CDMO Market Dynamics

The market for CDMOs capable of producing complex small molecule APIs like ruxolitinib is competitive. Major CDMOs offer broad service portfolios, but the specific expertise required for ruxolitinib synthesis may limit the pool of qualified manufacturers. Companies that can demonstrate strong track records in oncology API production, efficient process development, and scalable manufacturing are favored.

Excipient Market Concentration

The pharmaceutical excipient market is more consolidated, with a few large global players dominating the supply of standard pharmaceutical-grade excipients. However, for specialized or novel excipients, the market may be more fragmented or have fewer qualified suppliers. Companies that offer consistent quality, regulatory support, and reliable supply chains are key differentiators.

Supplier Qualification as a Barrier to Entry

The rigorous qualification process for pharmaceutical suppliers acts as a significant barrier to entry. New companies must invest heavily in quality systems, regulatory compliance, and manufacturing infrastructure to become approved suppliers. This favors established companies with long-standing relationships and proven performance.

Geographic Diversification of Suppliers

Pharmaceutical companies increasingly seek to diversify their supplier base geographically to mitigate risks. This trend encourages the development of manufacturing capabilities in multiple regions, potentially increasing competition among suppliers in different countries.

Key Takeaways

• Jakafi's supply chain involves specialized suppliers for its active pharmaceutical ingredient (API), ruxolitinib, key intermediates, and pharmaceutical-grade excipients.
• Major CDMOs like Lonza, Catalent, and WuXi AppTec are likely involved in API and intermediate manufacturing, requiring advanced organic synthesis and GMP capabilities.
• Excipients are sourced from established global suppliers such as IFF, Ashland, JRS Pharma, and BASF, all adhering to stringent pharmaceutical quality standards.
• Regulatory compliance, particularly cGMP, is critical for all suppliers. They must maintain robust quality management systems and often submit Drug Master Files (DMFs) for APIs.
• Potential supply chain risks include single-source dependence, geopolitical instability, raw material price volatility, natural disasters, and logistical disruptions.
• The competitive landscape for API suppliers is characterized by specialized capabilities and regulatory hurdles, while the excipient market is more consolidated with key global players.

Frequently Asked Questions

1. How does Incyte or Novartis qualify new suppliers for Jakafi components?

Incyte and Novartis employ a multi-stage qualification process that includes initial supplier assessment, detailed questionnaires, on-site audits of manufacturing facilities and quality systems, and pilot batch production followed by rigorous testing. They verify compliance with cGMP, assess technical capabilities, and evaluate the supplier's financial stability and supply chain reliability.

2. What is the typical lead time for qualifying a new API supplier?

Qualifying a new API supplier is a lengthy process, typically ranging from 12 to 24 months. This period accounts for comprehensive audits, process validation, establishment of analytical methods, stability studies, and regulatory submissions, if required.

3. Can a shortage of a specific excipient impact Jakafi's availability?

Yes, a shortage of a critical excipient, even if the API is readily available, can halt the production of the final drug product. Excipients are essential for the tablet's formulation, stability, and dissolution properties, and regulatory authorities require strict control over their quality and consistent supply.

4. How do regulatory changes in countries like China or India affect Jakafi's supply chain?

New environmental regulations, stricter quality enforcement, or changes in labor laws in major manufacturing hubs like China and India can impact production costs, lead times, and the operational status of API and intermediate suppliers. Pharmaceutical companies must monitor these changes and work with their suppliers to ensure continued compliance and uninterrupted supply.

5. Are there any generic versions of Jakafi currently on the market or in development, and how would that impact the supplier landscape?

As of early 2024, Jakafi (ruxolitinib) is still under patent protection in major markets, limiting the presence of generic versions. However, as patents expire, generic manufacturers would seek to develop their own versions. This would lead to increased demand for ruxolitinib API and intermediates, potentially creating new opportunities for CDMOs and driving down API prices due to increased competition among suppliers.

Citations

[1] Incyte Corporation. (2023). 2022 Annual Report. [SEC Filing]. Retrieved from https://www.sec.gov/ (Specific filing details would be needed for an exact link, typically through EDGAR database)

[2] Novartis AG. (2023). 2022 Annual Report. [SEC Filing]. Retrieved from https://www.sec.gov/ (Specific filing details would be needed for an exact link)

[3] Lonza Group AG. (n.d.). CDMO Services. Retrieved from https://www.lonza.com/

[4] Catalent, Inc. (n.d.). API Development & Manufacturing. Retrieved from https://www.catalent.com/

[5] WuXi AppTec. (n.d.). Small Molecule Services. Retrieved from https://www.wuxiapptec.com/

[6] Bachem Holding AG. (n.d.). API Manufacturing. Retrieved from https://www.bachem.com/

[7] International Flavors & Fragrances Inc. (IFF). (n.d.). Pharmaceutical Excipients. Retrieved from https://www.iff.com/

[8] Ashland Inc. (n.d.). Pharmaceutical Excipients. Retrieved from https://www.ashland.com/

[9] JRS Pharma. (n.d.). Functional Excipients. Retrieved from https://www.jrspharma.com/

[10] BASF SE. (n.d.). Pharmaceutical Excipients. Retrieved from https://www.basf.com/

[11] Merck KGaA. (n.d.). MilliporeSigma Pharmaceutical Solutions. Retrieved from https://www.milliporesigma.com/

[12] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/

[13] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.ema.europa.eu/